Aktis Oncology (NASDAQ:AKTS) Trading Up 6.1% – What’s Next?

Shares of Aktis Oncology (NASDAQ:AKTS) rose 6.1% on Tuesday . The stock traded as high as $29.01 and last traded at $28.1850. Approximately 43,845 shares changed hands during trading, a decline of 87% from the average daily volume of 338,937 shares. The stock had previously closed at $26.56.

Wall Street Analyst Weigh In

Several brokerages recently commented on AKTS. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair started coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, HC Wainwright increased their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Trading Up 6.8%

The company’s 50-day moving average is $22.08. The firm has a market cap of $1.51 billion and a PE ratio of -75.08.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million during the quarter. Research analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.